Acute Coronary Syndrome (ACS) represents a spectrum of conditions associated with acute myocardial ischemia. The management of ACS has dramatically evolved over the years with advancements in pharmacologic and interventional strategies. This article provides an overview of the current best practices in ACS management.
Over the past decade, substantial advancements have been made in the management of ACS, particularly in the realm of pharmacotherapy and percutaneous coronary intervention (PCI). The development of more potent antiplatelet agents like prasugrel and ticagrelor has significantly reduced the risk of recurrent ischemic events. The advent of bioresorbable vascular scaffolds and drug-eluting stents has improved the outcomes of PCI by reducing the risk of in-stent restenosis.
Early diagnosis and risk stratification using tools such as the GRACE score is crucial in guiding management. High-risk patients benefit from early invasive strategies including coronary angiography and revascularization. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone of medical management. The choice of P2Y12 inhibitor should be individualized considering the patient's risk profile. Statin therapy should be initiated in all patients irrespective of their baseline LDL levels. Lifestyle modifications and cardiac rehabilitation form an integral part of secondary prevention.
Despite significant advancements, ACS remains a leading cause of morbidity and mortality worldwide. Future research should focus on refining risk stratification tools, developing novel therapeutic agents, and improving adherence to guideline-directed medical therapy. The potential of personalized medicine in optimizing ACS management is an exciting frontier to explore.
The management of ACS has come a long way, but the journey is far from over. As healthcare professionals, it is our responsibility to stay abreast with the latest advancements and best practices to provide optimal care to our patients. Continuous learning and adaptation are the keys to success in this ever-evolving field.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation